Article Sidebar

PDF
Date Published: 13/02/2023
Abstract Views: 355
Views PDF: 166
DOI: https://doi.org/10.51298/vmj.v521i1.3994
Issue
Vol. 521 No. 1 (2022)
Section
Các bài báo
How to Cite
Phạm , T. T. ., & Nguyễn, T. V. H. (2023). SURVEY ON THE CHANGE OF HBCrAg IN PATIENTS WITH HEPATITIS B BEFORE AND AFTER TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE 300mg. Vietnam Medical Journal, 521(1). https://doi.org/10.51298/vmj.v521i1.3994

SURVEY ON THE CHANGE OF HBCrAg IN PATIENTS WITH HEPATITIS B BEFORE AND AFTER TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE 300mg

Thị Thùy Phạm 1,, Thị Vân Hồng Nguyễn2
1 Bach Mai Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Object: Survey on the change of HBcrAg in patients with chronic hepatitis B before and after treatment with Tenofovir disoproxil fumarate 300mg. Method: A cross-sectional descriptive study was carried out on 101 patients with hepatitis B at the Department of Examination, Department of On-Demand Examination, and Gastroenterology Center of Bach Mai Hospital during the period from October 2020 to June 2022. Results: Serum HBcrAg concentration gradually decreased over time of treatment, from 5.94±1.36 initially to 5.50±1.47 after 3 months, 5.04±1.40 after 6 months and 4.92±1.34 after 12 months, the difference was statistically significant in serum HBcrAg levels at 3, 6 and 12 months compared with baseline (p<0.0001). In both HBeAg-positive and HBeAg-negative groups, serum HBcrAg levels also decreased gradually with the time of treatment. Conclusion: The HBcrAg biomarker should be introduced into routine clinical practice for the management, monitoring and prognosis of the patients with chronic hepatitis B.

Article Details

Keywords

HBcrAg, hepatitis B, Tenofovir disoproxil fumarate, Bach Mai hospital

References

(2010), "Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death", Gastroenterology. 138(5), 1747-54.
2. Inoue, T.andTanaka, Y. (2019), "The Role of Hepatitis B Core-Related Antigen", Genes (Basel). 10(5).
3. Kimura, T., Rokuhara, A., Sakamoto, Y. et al. (2002), "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load", J Clin Microbiol. 40(2), 439-45.
4. Bộ Y tế (2019), Quyết định số 3310/QĐ-BYT ngày 29 tháng 7 năm 2019 về việc ban hành hướng dẫn chẩn đóa, điều trị bệnh viên gan virut B, tế, Bộ Y, chủ biên.
5. European Association For The Study Of The Liver (2018), "EASL clinical practice guidelines: management of hepatocellular carcinoma", Journal of hepatology. 69(1), 182-236.
6. Mak, Lung-Yi, Wong, Danny Ka-Ho, Cheung, Ka-Shing et al. (2021), "First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients", BMC Gastroenterology. 21(1), 123.
7. Suzuki, Fumitaka, Suzuki, Yoshiyuki, Karino, Yoshiyasu et al. (2021), "Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study", BMC gastroenterology. 21(1), 1-10.
8. World Health Organization (2017), Global hepatitis report 2017, World Health Organization.